Prime Medicine (PRME) shares new September 2025 corporate presentation

Rhea-AI Filing Summary

Prime Medicine, Inc. furnished a corporate update through a new investor presentation posted on its website on September 8, 2025. The company made the presentation, dated September 2025, available as Exhibit 99.1 to this report under a Regulation FD disclosure item.

The material is being treated as furnished, not filed, which means it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other securities law filings unless specifically referenced.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001894562false00018945622025-09-082025-09-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________

FORM 8-K

___________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

September 8, 2025

Date of Report (date of earliest event reported)

___________________________________

Prime Medicine, Inc.

(Exact name of registrant as specified in its charter)

___________________________________

Delaware (State or other jurisdiction of incorporation)			001-41536 (Commission File Number)			84-3097762 (I.R.S. Employer Identification No.)
60 First Street Cambridge, MA 02141
(Address of principal executive offices and zip code)
(617) 465-0013
(Registrant's telephone number, including area code)

___________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common stock, par value $.00001 per share

PRME

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§250.12b-2 of this chapter).

Emerging growth company    ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On September 8, 2025, Prime Medicine, Inc. (the "Company") posted an updated corporate presentation to its website at https://investors.primemedicine.com/news-events. A copy of the corporate presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated herein by reference. Reference to the Company’s website is for inactive textual reference only and the content of the website should not be deemed incorporated by reference into this Current Report on Form 8-K.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 - Financial Statements and Exhibits

(d) Exhibits

Exhibit Number						Description
99.1						Corporate Presentation, dated September 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 8, 2025

Prime Medicine, Inc.
By:			/s/ Allan Reine
Name:			Allan Reine, M.D.
Title:			Chief Executive Officer

FAQ

What did Prime Medicine (PRME) disclose in this 8-K filing?

Prime Medicine, Inc. reported that it posted an updated corporate presentation on its investor website and furnished the same presentation as Exhibit 99.1 to this report.

When was the new Prime Medicine (PRME) corporate presentation posted?

The updated corporate presentation was posted on September 8, 2025 and is described in the filing as being dated September 2025.

Where can investors access Prime Medicine’s updated corporate presentation?

Investors can access the updated corporate presentation on Prime Medicine’s investor relations website at https://investors.primemedicine.com/news-events, and it is also included as Exhibit 99.1 to this report.

Is the Prime Medicine (PRME) presentation considered filed or furnished with the SEC?

The information in Item 7.01, including Exhibit 99.1, is expressly stated as being furnished and not deemed filed for purposes of Section 18 of the Exchange Act.

Does this Prime Medicine 8-K incorporate the presentation into other SEC filings?

The company states that the information in Item 7.01 and Exhibit 99.1 is not incorporated by reference into any Securities Act or Exchange Act filing, except where it may be expressly incorporated by specific reference in a future filing.

Who signed this Prime Medicine (PRME) 8-K report?

The report was signed on behalf of Prime Medicine, Inc. by Allan Reine, M.D., in his capacity as Chief Executive Officer on September 8, 2025.